Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α

Bao-Feng Wangac Xi-jing Wanga Hua-Feng Kangac Ming-Hua Baia Hai-Tao Guana Zhong-Wei Wanga Ying Zana Ling-Qin Songa Wei-Li Mina Shuai Lin a Yan-An Chengb

aDepartment of Oncology, the Second Affiliated Hospital of School of Medicine, Xi’an Jiaotong University, Xi’an, bDepartment of Infectious Disease, the Second Affiliated Hospital of School of Medicine, Xi’an Jiaotong University, Xi’an, P.R. China; cCo-first authors

Key Words
Hypoxia • HCC • Radiation • Cobalt chloride • HIF-1α

Abstract

Background: Our previous study revealed that the combination of Saikosaponin-d (SSd) and radiation is more effective in the treatment of liver cancer than the application of either of these monotherapeutic methods. However, the molecular mechanisms of the radiosensitizing effect of SSd on liver cancer remained ill defined. Methods: Cells were treated with different interventions; afterward, cell viability, apoptosis, and cell survival of SMMC-7721 and HepG2 hepatoma cells were examined. Xenograft tumor models were established by subcutaneously injecting SMMC-7721 cells. The molecular mechanism was assessed by western blot. Results: SSd dose-dependently increased radiosensitivity of hepatoma cells under hypoxic condition. The growth inhibitory effect of the combined treatment was correlated with cell apoptosis. Further mechanistic analysis indicated that SSd induced the upregulation of p53 and Bax as well as the downregulation of Bcl-2 by attenuating HIF-1α expression under hypoxic condition. These effects were enhanced when the HIF-1α inhibitor PX-478 was introduced. In vivo data also presented a more significant suppression of tumor xenograft growth from the combined therapy than from either of the monotherapeutic methods. Conclusions: Our study provides evidence for a radiosensitizing effect of SSd on hepatoma cells under hypoxic conditions by inhibiting HIF-1α expression. Thus, SSd can be used as a potential sensitizer in hepatoma radiotherapy.

Copyright © 2014 S. Karger AG, Basel
Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide; the incidence of HCC has increased for several decades [1–3]. In many cases, HCC is developed from viral hepatitis and cirrhosis. Although many treatment strategies, such as surgical resection, liver transplantation, radiotherapy, and chemotherapy, have been introduced, patient survival has not evidently improved. This problem occurs because HCC has reached an advanced stage at the time of clinical presentation; therapeutic options at this stage are very limited. In recent years, new technologies, including three-dimensional conformal radiotherapy and intensity modulated radiation therapy, have been used to treat patients with advanced HCC [4–6]. However, the presence of hypoxic tumor cells that are more invasive, metastatic, and radioresistant influences radiotherapeutic outcomes [7, 8].

Hypoxia is a common characteristic of rapidly growing malignant tumors that promote cancer progression, cause resistance to radiotherapy and chemotherapy, and predict poor overall patient survival. Hypoxia-inducible factor-1α (HIF-1α) in tumor cells can increase radiation resistance and tumor angiogenesis [9, 10]; HIF-1α expression can be induced by radiation [11]. Studies have demonstrated that HIF-1α expression in tumor cells can be inhibited; as a result, tumor angiogenesis may be reduced and tumor radiosensitivity may be enhanced, thereby inhibiting the growth of xenografted tumors [11–13].

Saikosaponin-d (SSd), an extract from a traditional Chinese herb, Bupleurum chinensis DC, exhibits various pharmacological properties, such as anti-inflammation [14, 15], hepatocyte injury prevention [16], angiogenesis inhibition [17], and anti-cancer [18, 19]. In our preliminary experiments, SSd and radiation are administered to treat liver cancer; the results have revealed that this combined treatment is more effective than either of these treatments administered alone. This result has indicated that SSd contributes to the effects of radiotherapy. We also observed that SSd elicits anti-cancer effect at a low extent, but SSd remarkably enhances the radiosensitivity of tumor cells when used at a very low concentration. Considering that HIF-1α expression in tumor cells is a key factor of radioresistance, we assumed that SSd may increase radiosensitivity by inhibiting HIF-1α-active hypoxic tumor cells. To verify this hypothesis, we established an in vitro CoCl₂-induced hepatoma hypoxia model and an in vivo mouse xenograft tumor model. We used these models to investigate the response of hepatoma to SSd when administered alone or combined with radiation.

Materials and Methods

Reagents and antibodies
PX-478-, HIF-1α-, and VEGF-specific monoclonal antibodies were purchased from Millipore Co. (USA). SSd and CoCl₂ were obtained from Sigma Chemical (St. Louis, MO). Hypoxyprobe™-1 Kit was supplied by Hypoxyprobe Inc. (Burlington, MA). P53, Bax, Bcl-2, and β-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

Cell culture and hypoxia model
Two hepatoma cell lines, SMMC-7721 and HepG2, were purchased from the Medical Experimental Animal Center of the Fourth Military Medical University (Xi’an, China). The cells were cultured in RPMI-1640 medium (PAA Laboratories GmbH, Austria) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin G, and 100 µg/ml streptomycin sulfate (GIBCO, Invitrogen) in a humidified atmosphere containing 5% CO₂ at 37 °C. These cells grown to 80% to 90% confluence were trypsinized, counted, and seeded in a six-well plate to induce hypoxia. The cells were incubated with 100 µM CoCl₂ for 4 h in 4 ml of serum-free medium and then exposed to X-ray irradiation at a dose rate of 400 cGy/min (Clinac 2100EX; Varian Medical Systems Inc., CA) [20, 21]. Immediately after irradiation, the medium was replaced with fresh RPMI-1640 containing 10% FBS and the cells were incubated at 37 °C for 24 h before cell viability was determined. In addition, hypoxia was made by placing cells in a microaerophilic incubation system...
Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α

Cellular Physiology and Biochemistry

(Bugbox-M, Ruskinn, Bridgend, UK) with humidified 1% O₂, 5% CO₂, and 94% N₂. The control cultures were incubated in oxic conditions of humidified 21% O₂.

**SSd preparation and experimental groups**

SSd was dissolved in dimethylsulfoxide (DMSO, Sigma, St. Louis, MO, USA) and stored at –20°C. The desired final concentrations were obtained by diluting with RPMI-1640. SMMC-7721 and HepG2 cells were treated with radiation alone, SSd alone, or a combination of radiation and SSd. Radiation was performed at different doses (2, 4, 6, and 8 Gy, 6 MV, and a dose rate of 400 cGy/min) by using an X-ray linear accelerator at room temperature. SSd was also administered at different concentrations (1, 3, 5, 10, and 20 µg/ml). SSd was added to the cultures at 2 h before irradiation. Control cultures received a carrier solvent consisting of 0.1% DMSO.

**Cell viability determination**

Cell viability was detected by MTT assay under oxic condition or CoCl₂-induced hypoxic condition after 4 h of chemical hypoxic culture. SMMC-7721 and HepG2 cells were seeded in a 96-well plate (5 x 10³ cells/well) and incubated at 37 °C in 5% CO₂ for different periods as desired. MTT solution (5 mg/ml; Sigma, St. Louis, MO, USA) was added (20 µl/well) and the cells were incubated for another 4 h. Supernatants were removed and formazan crystals were dissolved in 200 µl of DMSO. Optical density was determined at 492 nm by using a multi-microplate test system (POLARstar OPTIMA, BMG Labtechnologies, Germany). The assay was conducted in quadruplicate.

**Cell survival analysis**

The cells in the monolayer culture were exposed to SSd or 0.1% DMSO for 24 or 48 h and irradiated with graded doses of X-ray by using a linear accelerator at a dose rate of 400 cGy/min. The cells that remained attached were removed from the culture flask by exposing to 0.05% trypsin/1 mM EDTA solution. Afterward, these cells were re-plated in specified numbers in 60 mm dishes containing a drug-free medium to determine the colony-forming ability. After 10 d of incubation, the dishes were stained with 0.5% crystal violet in absolute methanol, and the colonies with more than 50 cells were counted. The colony-forming rate was defined as the number of colonies divided by the number of cells seeded at 0 Gy. The survival fraction (SF) was calculated by dividing the number of colonies at a certain radiation dose by the product of the number of cells seeded at this dose and the corresponding colony-forming rate. The sensitization enhancement ratio (SER) at 50% cell survival was obtained by dividing the dose of radiation from the radiation-only surviving curve by the corresponding dose from the SSd plus radiation curve. Each data point was calculated as the percent of untreated cells in two independent experiments each performed in duplicates.

**Apoptosis assay**

*In vitro* cell apoptosis was detected by flow cytometry using an Annexin V-FITC apoptosis detection kit (BD Bioscience Co., USA). In brief, the cells in the tumor samples were double stained with Annexin V-FITC and propidium iodide (PI) according to the manufacturer’s instructions. Early apoptosis and late apoptosis were determined by Annexin V+/PI– staining (Q4) and Annexin V+/PI+ staining (Q2), respectively. The percentage of apoptotic cells in each sample was examined using a FACSCalibur™ flow cytometer (Becton Dickinson Technologies, USA) and compared with the control samples.

To determine cell apoptosis *in vivo*, 5 µm tissue sections were deparaffinized in xylene and hydrated in decreasing ethanol concentrations. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed according to the manufacturer’s instructions (Keygen, Nanjing, China). A total of 10 random fields from four slides per group were examined. TUNEL-positive brown nuclei in the tissue were counted. Data were expressed as the mean number of apoptotic cells divided by the number of high power fields.

**Xenograft tumor model and treatment**

A therapeutic study was conducted on SMMC-7721 xenograft tumor models. Male BALB/c nude mice (age = four weeks) were purchased from the Experimental Animal Center of School of Medicine, Xi’an Jiaotong University (Xi’an, China). The tumor model was established by subcutaneously (s.c.) injecting 2 ×
10⁶ SMMC-7721 cells (0.2 mL) in the left leg of each mouse. After the tumors reached a mean volume of 300 mm³ to 400 mm³, the mice were randomly distributed into four groups (n = 6): SSd, radiation, combined, and control groups. The mice in the SSd group were intraperitoneally injected with SSd at a dose of 0.75 mg/kg body weight thrice a week for two weeks. This dose was administered based on the result of our preliminary experiment, which is 10% of the dose with the median effective concentration (EC₅₀) of SSd when administered alone. The mice treated by radiation alone wereimmobilized in a customized harness. The right leg was exposed and the remaining parts of the body were shielded with a thick (7 cm) piece of lead. The tumor area was irradiated with a single dose of 10 Gy at a dose rate of 500 cGy/min by using an X-ray linear accelerator. The mice in the group treated with the combined SSd and radiation were irradiated with 10 Gy at 24 h after the third injection of SSd in the first week. The control group received a vehicle consisting of 0.1% DMSO.

Tumor growth was monitored by measuring the tumor size in two orthogonal dimensions with vernier calipers every 5 d; the tumor volume was calculated according to the following formula: [length × (width²)] × 0.5 [22, 23]. The mice were anesthetized and sacrificed three weeks after the final treatment. The tumors were surgically excised, weighed, fixed in 10% formalin, embedded in paraffin, and cut into thick slices (4 µm) for hematoxylin and eosin staining (H&E). Inhibition rate was defined as: [1 – tumor weight or volume of the treatment group / tumor weight or volume of the control group]. In addition, the tumor-bearing mice were intraperitoneally injected with pimonidazole hydrochloride (60 mg/kg), and the solid tumors were then surgically removed and fixed in 10% formalin neutral buffer solution after 60 min. Immunohistochemical staining of pimonidazole was performed according to a standard protocol using a Hypoxyprobe™-1 kit. The primary antibodies to pimonidazole (1:100) were selected. PBS, instead of primary antibody, was used as a negative control. Pimonidazole positive staining was judged according to the methods provided by Nordsmark [24]. Data were representative of three independent experiments. All of the animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Experimental protocols were approved by the Animal Care and Use Regulation of Xi’an Jiaotong University.

Western blot
Western blot analysis was performed as described previously [23]. In brief, aliquots of cell lysates containing 40 µg of protein were separated on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (Millipore Billerica, MA). The blots were probed with antibodies against HIF-1α (diluted 1:200), VEGF (diluted 1:200), p53 (diluted 1:100), Bel-2 (diluted 1:100), and Bax (diluted 1:100). The membranes were incubated in the dark with ECL (Amersham) to detect chemiluminescence. Luminescent signals were detected using a CCD camera, recorded, and quantified using a Syngene G Box (Syngene, UK). The membranes were re-probed for β-actin as loading control. Analysis was conducted at least thrice for each experiment.

Statistical analysis
Quantitative data were presented as the mean ± standard error of the mean (SEM) and analyzed by one-way ANOVA. Statistical analyses were performed using SPSS software (version 13.0). Tukey’s post hoc analyses were conducted to assess the difference between groups. Data were considered significant if P < 0.05.

Results

Effect of SSd on cell growth and apoptosis
The chemical structure of SSd is shown in Fig. 1A. Cell growth in response to SSd treatment was assessed under oxic or hypoxic condition. Cell viability was determined at 48 h after treatment. Fig. 1B shows that the cell viabilities of HepG2 and SMMC-7721 cells were significantly reduced in a dose-dependent manner under oxic and CoCl² conditions. IC₅₀ was 13.2 µg/ml for SMMC-7721 and 17.7 µg/ml for HepG2 cells under oxic conditions; IC₅₀ was 14.3 µg/ml for SMMC-7721 and 19.7 µg/ml for HepG2 under CoCl² conditions.

Cell apoptosis induced by SSd, radiation, or both was determined by flow cytometry. PX-478 was used as a positive control. The results showed that ≥3 µg/ml of SSd significantly
induced apoptosis of the two cell lines (Figs. 1C and 1D) under oxic and CoCl$_2$ conditions compared with the control cells ($P < 0.05$). Induced apoptosis increased in both cell lines under oxic condition compared with the cells under CoCl$_2$ condition, but the difference was not significant (Figs. 1C and 1D, $P > 0.05$). At 2 Gy of radiation, the percentage of apoptotic cells under oxic condition was higher than that under CoCl$_2$ condition in both cell lines (Figs. 1C and 1D, $P < 0.05$). The combined therapy induced the apoptosis of both cell lines at a greater extent under both oxic and CoCl$_2$ conditions than either SSd or radiation therapy alone. SSd did not induce apoptosis in the cell lines when used alone at a low dose (1 µg/ml). By contrast, the combined treatment at the same concentration exhibited a synergistic effect on apoptosis induction. In SMMC-7721 cell line, the apoptosis rates under CoCl$_2$ condition were 10.46% in the radiation group and 27.85% in the combined treatment group (Fig. 1C, $P < 0.01$). A similar change was observed in HepG2 cell line, in which the apoptosis rates were 8.37% and 25.78% in radiation and combined treatment groups, respectively (Fig. 1D, $P < 0.01$). The synergistic effect of SSd on radiation-induced apoptosis was more evident under CoCl$_2$ condition than under oxic condition. This effect was observed in a dose-
Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α

Fig. 2. Survival curves of SMMC-7721 and HepG2 cells exposed to different interventions. A. C. SSd alone at different concentrations. B. D. Radiation alone and combined effects of radiation with SSd (3 μg/ml). E. F. Surviving fractions of the two cell lines exposed to different interventions. G. Surviving fractions of the SMMC-7721 cell under oxic or hypoxic condition. H. Surviving fractions of the HepG2 cell under oxic or hypoxic condition. The survival curves show a pronounced decrease in cell colony formation and an evident increase in cell radiosensitivity especially under CoCl₂ or hypoxic condition, and the effect appeared to be dose-dependent. The surviving fraction was determined as a percentage with respect to control cells. Data are shown as mean ± SD *P < 0.05, **P < 0.01.

dependent manner (Figs. 1C and 1D, P < 0.05). PX-478 further enhanced this effect under CoCl₂ condition. Similarly, the synergistic effect of SSd on radiation-induced apoptosis was also observed under hypoxic conditions (1% O₂, 5% CO₂, and 94% N₂) (Figs. 1E and 1F, P < 0.01).
Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α

**Cellular Physiology and Biochemistry**

**Effect of SSd on cell colony formation**

SMMC-7721 and HepG2 cell lines were treated with SSd, radiation, or a combination of SSd (3 µg/mL) and radiation (2, 4, 6, and 8 Gy). Untreated cells were used as the control. The cells were re-plated at certain dilutions after treatment and the surviving colonies were counted after 10 d. A more evident, dose-dependent decrease in cell survival was observed in the combined treatment group than in SSd or radiation group, particularly under CoCl$_2$.
condition (Fig. 2; \( P < 0.01 \)). SFs of SMMC-7721 cells were 0.75 and 0.91 under oxic and CoCl_{2} conditions, respectively; when the cells were exposed to 2 Gy of radiation (Fig. 2B). SFs of HepG2 cells were 0.76 and 0.92 under oxic and CoCl_{2} conditions, respectively (Fig. 2D). This result indicated that radiation alone did not effectively inhibit the cell survival under CoCl_{2} condition as observed under oxic condition. After SSd (3 \( \mu \)mol/L) was combined with radiotherapy, SF of SMMC-7721 cells at 2 Gy of radiation decreased to 0.54 under CoCl_{2} condition (Fig. 2B). SF of HepG2 cells also decreased to 0.55 (Fig. 2D). SERs were 1.72 and 1.74 in SMMC-7721 and HepG2 cells, respectively. The radiosensitivity of the cell lines under CoCl_{2} condition was further enhanced after the intervention of PX-478 (Figs. 2E and 2F). This effect was not observed under oxic condition. In addition, the radiosensitization effect of SSd was enhanced as SSd concentration increased, indicating that radiosensitivity was affected in a dose-dependent manner. Additionally, under hypoxic conditions (1% \( O_{2} \), 5% \( CO_{2} \), and 94% \( N_{2} \)), we also observed that SSd further decreases the SFs of radiation on SMMC-7721 cells or HepG2 cells (Figs. 2G and 2H). These results provided additional evidence that SSd may be a potent radiosensitizer in tumor cells.

**Effect of SSd on HIF-1α and VEGF protein expression**

The expression levels of HIF-1α protein in SMMC-7721 and HepG2 cells were examined to investigate the mechanism of radiosensitization of SSd on hematoma cells under hypoxic condition. The cells were incubated with 100 \( \mu \)mol CoCl_{2} for 4 h in a serum-free medium. Low HIF-1α expression was detected in both cell lines before the CoCl_{2} treatment; this result is probably due to the rapid protein degradation under oxic conditions [25]. By contrast, the protein was expressed after the CoCl_{2} treatment (Figs. 3A and 3F). Radiation in the presence of CoCl_{2} killed fewer cells than in the absence of CoCl_{2} (Figs. 2B and 2D, \( P < 0.05 \)). The ability of radiation to kill tumor cells was significantly enhanced when SSd was added (Figs. 2B and 2D, \( P < 0.01 \)). HIF-1α expression also decreased under CoCl_{2} conditions (Figs. 3B and
Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α

After the cells were treated with PX-478, HIF-1α expression decreased under CoCl₂ conditions (Figs. 3A, 3B, 3F, and 3G, P < 0.01), cell radioresistance disappeared, and cell apoptotic rate increased significantly (Figs. 1C and 1D, P < 0.01). The lowest HIF-1α expression was observed in the cells treated with PX-478 and SSd under CoCl₂ condition. This result showed that HIF-1α expression correlated negatively with cell radiosensitivity.

In addition, we examined the VEGF expression of HIF-1α downstream genes in SMMC-7721 and HepG2 cells. The results showed that the upregulation or downregulation of VEGF expression is consistent with HIF-1α expression after our intervention (Figs. 3A, 3E, 3F, and 3J). Similarly, the expression levels of HIF-1α protein in SMMC-7721 and HepG2 cells were significantly reduced under hypoxic conditions (1% O₂, 5% CO₂, and 94% N₂) (Fig. 4, P < 0.01), after treated with the combination of SSd and radiation. These results also suggested that CoCl₂ or hypoxia-induced HIF-1α overexpression functioned in cellular resistance to radiation, whereas SSd elicited an inhibitory effect on HIF-1α expression in tumor cells under hypoxic conditions.
Effect of SSd on radiation-induced p53 and Bax/Bcl-2 expressions

The tumor suppressor p53, also known as a “gatekeeper” protein, has a critical function in preventing cancer development by initiating cell apoptosis. P53 can induce the expression of pro-apoptotic Bax protein [26, 27] and suppress the expression of anti-apoptotic Bcl-2 [28, 29], resulting in apoptosis [30, 31]. In our experiments, p53 level in the tumor cells did not change under CoCl$_2$ condition (Figs. 3A and 3F). At 2 Gy of radiation, p53 protein expression increased in SMMC-7721 and HepG2 cells under oxic or CoCl$_2$ conditions (Figs. 3A and 3F, $P < 0.01$). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F). A greater increase in p53 expression was induced in cells treated with the combined therapy under oxic (2.7-fold for SMMC-7721 and 2.5-fold for HepG2) and CoCl$_2$ (3.5-fold for SMMC-7721 and 3.3-fold for HepG2) conditions (Figs. 3A and 3F).

Therapeutic efficacy of SSd in xenografted SMMC-7721 model in BALB/c nude mice

This experiment was performed to compare the efficacy of monotherapy with the combined therapy on tumor growth in vivo. SSd administered at a dose of 0.75 mg/kg showed a modest inhibition of tumor growth compared with the control group, resulting in 11% reduction in tumor weight. By contrast, radiation at a dose of 10 Gy significantly inhibited tumor growth, resulting in 33% reduction in tumor weight at the end of the
Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α

Cellular Physiology and Biochemistry

The combined SSd and radiation also resulted in 66% reduction in tumor weight (Fig. 5E, P < 0.001). Tumor growth slowed down and reached the minimum level at 13 d after irradiation; the tumor volume obtained at this time was only 47% of the tumor volume of the control group (Fig. 5D). The experiment was terminated three weeks after the final injection of SSd. The mice were sacrificed and the tumor tissues were examined to determine HIF-1α expression. HIF-1α expression increased in the cells treated with radiation alone compared with that in the control group; by contrast, HIF-1α expression decreased in the cells treated with either SSd alone or the combined regimen (Figs. 6A and 6B, P < 0.05). In addition, we further assess tumor hypoxia by performing pimonidazole immunohistochemistry of tumor tissue using a Hypoxyprobe™-1 Kit. The results also showed that after treated with the combination of SSd and radiation, the number of pimonidazole positive cells and the staining intensity was significantly lower than the control group. (Fig. 7, P < 0.01).

TUNEL assay was conducted; p53, Bax, and Bcl-2 expressions were examined. As expected, the combined therapy significantly induced apoptosis as shown by an increased number of apoptotic cells compared with that in the control group; by contrast, HIF-1α expression decreased in the cells treated with either SSd alone or the combined regimen (Figs. 6A and 6B, P < 0.05). In addition, we further assess tumor hypoxia by performing pimonidazole immunohistochemistry of tumor tissue using a Hypoxyprobe™-1 Kit. The results also showed that after treated with the combination of SSd and radiation, the number of pimonidazole positive cells and the staining intensity was significantly lower than the control group. (Fig. 7, P < 0.01).

Discussion

HIF-1α overexpression in human cancer cells is correlated with the poor response of tumor cells to radiotherapy and poor prognosis [10, 32]. Therefore, HIF-1α is considered as a potential therapeutic target and HIF-1α inhibition is a promising strategy to treat cancer. The in vitro experiments in this study showed that SSd could enhance the radiosensitivity of SMMC-7721 and HepG2 cell lines irradiated under oxic and hypoxic conditions. SSd could inhibit the expressions of HIF-1α and VEGF more effectively in cells irradiated under hypoxic condition than under oxic condition. The cells exposed to the combined treatment exhibited cell apoptosis with a higher Bax/Bcl ratio than those treated with either SSd or
radiation alone. The combined treatment also increased p53 expression in cells. The in vivo experiments revealed that the combined treatment more evidently inhibited tumor growth than either of the monotherapies. Tumor growth was significantly slowed down and cell apoptosis occurred at a high rate after the combined treatment. The remarkable decrease in HIF-1α expression in the cells treated with SSD alone or SSD and radiation indicated that SSD possibly inhibited HIF-1α expression in tumor cells and enhanced tumor radiosensitivity.

SSD can increase radiation-induced apoptosis of tumor cells and reduce cell colony formation under oxic conditions. Under oxic conditions, HIF-1α and VEGF expression levels were low in the tumor cells; these expressions increased to a certain extent after irradiation. Although SSD and radiation were combined, a significant change was not observed in HIF-1α and VEGF expression. This result indicated that the increase in radiosensitivity caused by SSD under oxic conditions is unlikely a result of inhibited HIF-1α and VEGF expressions. This finding is consistent with that in other studies, in which SSD involves many other mechanisms in tumor growth inhibition [18, 19]. The molecular mechanisms of the radiosensitization effect of SSD under oxic condition need further investigation. In the present study, HIF-1α and VEGF expression levels in tumor cells under hypoxic conditions were significantly higher. The cells also showed higher radioreistance level; the inhibition of radiation-induced apoptosis and colony formation was significantly reduced. SSD induced a decrease in HIF-1α and VEGF expressions; the ability of radiation to kill tumor cells when combined with SSD was significantly enhanced. In addition, PX-478 inhibited tumor growth more effectively as indicated by a higher HIF-1α activity under CoCl₂ condition than under oxic condition. This finding is consistent with that in previous reports [33–35]. With the co-intervention of PX-478 and SSD, radiosensitivity of tumor cells under CoCl₂ conditions decreased significantly as HIF-1α and VEGF expressions in the cells further decreased. The ability of radiation to kill tumor cells was enhanced. However, this enhancement was not observed under oxic conditions. Therefore, the radiosensitization effect of SSD under hypoxic conditions could be attributed to the inhibition of HIF-1α expression.

The precise mechanism of radiosensitivity enhancement in cells pre-incubated with SSD remains unclear. The p53 protein is likely the most thoroughly studied tumor suppressor involved in preventing cancer development by regulating numerous cellular processes that participate in DNA repair after genotoxic stress [36, 37]. In addition to the ability of p53 to initiate apoptosis of damaged cells, the level of p53 is influenced by radiation treatment [38, 39]. A study has found that pre-irradiation treatment with adenovirus-mediated p53 may significantly increase the radiosensitivity of tumor cells [40]. Anti-cancer functions of p53 are largely demonstrated by an apoptosis-inducing ability. P53 can also induce the expression of pro-apoptotic Bcl-2 family members, such as Bax, Bid, Noxa, and Puma [26, 27], which activates caspase-3, in the apoptosis pathway [30, 31]. By contrast, p53 suppresses the expression of anti-apoptotic genes such as Bcl-2, Bcl-xL, and survivin [28, 29].

We found in our experiments that CoCl₂ alone has no effect on p53 expression in tumor cells, whereas radiation can induce the increase in p53 protein level in oxic and CoCl₂-treated cells. Equal doses of radiation produce a higher survival rate in CoCl₂-treated cells than in oxic cells. This result corresponds to the changes observed in p53 levels after equal doses of radiation were administered, in which p53 levels are significantly increased in oxic cells but not in CoCl₂-treated cells. P53 is known to have a major function in the induction of apoptosis as a result of radiation treatment [30, 38]. Downstream effectors of p53 were examined after irradiation. The results showed a more significant upregulation of pro-apoptotic Bax and Bax/Bcl-2 ratio under oxic condition than under CoCl₂ condition. By contrast, the expression of Bcl-2 is more remarkably downregulated under oxic condition and tumor cell apoptosis rate is significantly higher. Ayelet et al. [41] reported similar results of TK6 human lymphoblastoid cells. These findings suggested that the induction of p53 is a radiation-specific stimulus in oxic and CoCl₂-treated tumor cells; the radiosensitizing effect of SSD on hepatoma cells may be closely associated with p53.

The high expression of HIF-1α under hypoxic conditions may inhibit p53 expression, resulting in the radioreistance of tumor cells [42, 43]. Our in vitro study showed that the
HIF-1α expression decreased as p53 inhibition was relieved under CoCl₂ condition after the combined therapy was administered. The in vivo experiment also revealed a decrease in HIF-1α and pimonidazole expression and an increase in p53 levels after the intervention of SSD in radiation treatment. These findings suggested that the radiosensitization effect of SSD under hypoxic conditions may be observed by enhancing p53 expression caused by the inhibition of HIF-1α expression.

In conclusion, the radiosensitization effect of SSD on hepatoma cells was demonstrated for the first time. The mechanism of this effect may involve the inhibition of HIF-1α expression by SSD in hypoxic tumor cells. Our experimental data suggested that the radiosensitization effect of SSD on hepatoma cells may be closely related to the p53 expression in cells, but this association should be further verified. The findings in this study indicated that SSD may be a potential sensitizer in liver cancer radiotherapy.

Conflict of Interest

All authors have no financial and personal relationships with other people or organizations that may inappropriately influence (bias) their work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 30973810).

References

Wang et al.: Saikosaponin-d Enhances Radiosensitivity by Inhibiting HIF-1α


